Infectious disease
Hong Kong-based Prenetics Group Limited, a medical diagnostic startup, is making its debut on the Nasdaq through a merger with Artisan Acquisitions Corp. The deal is valued at $1.25 billion.
FDA external advisors will meet to consider Pfizer and BioNTech data in support of booster shots. The two companies also expect to file for Vaccine Authorization for children in the coming months.
Data coming in about the COVID-19 pandemic shows some promising overall trends, with other more disturbing ones, particularly in breakthrough infections of the fully vaccinated.
According to the study, people who get sick enough to be hospitalized due to the virus might eventually suffer from a full-blown autoimmune disease later on.
CureVac NV is downsizing its European mRNA production network due to decreased demand for vaccines after the first wave of vaccinations.
Takeda announced that the company plans to grow its vaccines business. CEO Christophe Weber discussed this today in an interview at Reuters Events’ Pharma Japan 2021 conference.
Recently, the National Institutes of Health (NIH)'s removal of genetic data about the COVID-19 virus from its archive was brought into the spotlight.
Everest will pay Providence $50 million in cash upfront for access to its COVID-19 vaccine and other mRNA vaccine candidates targeting specific variants in earlier stages of development.
Dr. Scott Gottlieb estimated that a vaccine for the 5-11-year-old age group could be available by Halloween – in a best-case scenario.
The Phase II study showed enhanced immune memory response to the virus in 96% of vaccinated subjects, all of whom were exposed to an environment dominated by the delta variant.
PRESS RELEASES